Indexed in

License and use

Citations

Cited 1 times in

Cited 1 times in

Altmetrics

Grant support

This study has been supported by a grant from "Fundacion Unoentrecienmil"; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociacion Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundacion Sonrisa de Alex& Todos somos Ivan (TVP 1324/15); Consejeria de Educacion, Junta de Castilla y Leon (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigacion del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundacion AMPILE. J.M.H.S. is supported with a research grant by FEHH ("Fundacion Espanola de Hematologia y Hemoterapia"), A.M. a grant from Junta provincial de Salamanca de la Asociacion Espanola Contra el Cancer (AECC), and M.M. holds the grant "Ayuda predoctoral de la Junta de Castilla y Leon" by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).

Analysis of institutional authors

Share

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

Publicated to:Journal Of Personalized Medicine. 10 (4): 1-15 - 2020-12-01 10(4), DOI: 10.3390/jpm10040244

Authors: Vega-Garcia, Nerea; Benito, Rocio; Esperanza-Cebollada, Elena; Llop, Marta; Robledo, Cristina; Vicente-Garces, Clara; Alonso, Javier; Barragan, Eva; Fernandez, Guerau; Hernandez-Sanchez, Jesus M; Martin-Izquierdo, Marta; Maynou, Joan; Minguela, Alfredo; Montano, Adrian; Ortega, Margarita; Torrebadell, Montserrat; Cervera, Jose; Sanchez, Joaquin; Jimenez-Velasco, Antonio; Riesco, Susana; Hernandez-Rivas, Jesus M; Lassaletta, Alvaro; Fernandez, Jose Maria; Rives, Susana; Dapena, Jose Luis; Ramirez, Manuel; Camos, Mireia

Affiliations

Abstract

The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (Oncomine(TM) Childhood Cancer Research Assay; Archer(R)FusionPlex(R) ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2(R)). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.

Keywords